A Phase II Study of CCI-779 [temsirolimus] in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer.
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2016
At a glance
- Drugs Temsirolimus (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 21 Sep 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
- 27 Sep 2011 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.